BioRationality: Questioning Experts and Journals Reporting on Biosimilar Bill to Remove Interchangeability

June 23, 2025

The debate over the Biosimilar Red Tape Elimination Act raises critical concerns about FDA standards, physician trust, and patient safety in biosimilars.

Long-Term Durability and Cost-Effectiveness of Adalimumab Biosimilars in Pediatric IBD

June 22, 2025

The Top 5 Biosimilars Articles for the Week of June 16

June 20, 2025

Tocilizumab Biosimilar CT-P47 Shows Promise for Rheumatoid Arthritis Self-Administration

June 19, 2025

Strengthening Diabetes Care With Purpose-Built Data Infrastructure

June 18, 2025

Clinical Evidence Shows No Safety Gaps Between Biosimilar, Reference Adalimumab

April 26th 2025

By Deana Ferreri, PhD

Article

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the originator in a pooled analysis of the VOLTAIRE clinical trials.

The Top 5 Biosimilar Articles for the Week of April 21

April 25th 2025

By Skylar Jeremias

Article

Here are the top 5 biosimilar articles for the week of April 21, 2025.

Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market

April 25th 2025

By Cameron Santoro

Article

Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.

Unlocking Biosimilar Potential in Specialty Pharmacies With Legislative Support, Formulary Changes

April 24th 2025

By Cameron Santoro

Article

Sophia Humphreys, PharmD, MHA, BCBBS, emphasized that legislative support and formulary changes are crucial for overcoming unique challenges in specialty pharmacies and driving the growth of biosimilar adoption, which has significant cost saving potential in the next decade.

Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain

April 24th 2025

By Cameron Santoro

Article

Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.

The Growing Impact of Biosimilars in IBD Care

April 23rd 2025

By Skylar Jeremias

Article

Biosimilars are proving to be a game-changing solution in the fight against inflammatory bowel disease (IBD), offering a cost-effective alternative to biologics with similar efficacy and safety, while innovative drug delivery systems promise to further enhance treatment outcomes and accessibility for millions worldwide.

Eye on Pharma: Sandoz Files Antitrust Suit; Yuflyma Interchangeability; Costco’s Ustekinumab Pick

April 22nd 2025

By Skylar Jeremias

Article

Sandoz's antitrust suit against Amgen, the FDA’s interchangeability designation for Celltrion’s adalimumab biosimilar, and the inclusion of an ustekinumab biosimilar in Costco’s prescription program highlight growing momentum to expand biosimilar access and affordability for patients with chronic inflammatory diseases.

BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars

April 21st 2025

By Sarfaraz K. Niazi, PhD

Article

Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.

Biosimilar and Biologic Use Increasing in Greek Patients With IBD

April 19th 2025

By Deana Ferreri, PhD

Article

A retrospective study from a single inflammatory bowel disease (IBD) center in Greece reported that from 2018 to 2022, the use of biologics increased by 28% yearly, and the proportion of patients using biosimilars grew from 33% to 67%.

The Top 5 Biosimilar Articles for the Week of April 14

April 18th 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of April 14, 2025.